Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Acute Lymphoblastic Leukemia – Current Treatment – Acute Lymphoblastic Leukemia | Current Treatment: Physician Insights | US
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US
Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…
Hodgkin’s Lymphoma – Epidemiology – Epidemiology – Hodgkin’s Lymphoma – Mature Markets
Clarivate Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Hemolytic Disease of the Fetus and Newborn – Executive Insights – Hemolytic Disease of the Fetus and Newborn | Executive Insights | US/EU5
Hemolytic disease of the fetus and newborn (HDFN), also known as alloimmune HDFN or erythroblastosis fetalis, is a rare red blood cell disorder in which maternal antibodies attack the red blood…
Fetal and Neonatal Alloimmune Thrombocytopenia – Executive Insights – Fetal and Neonatal Alloimmune Thrombocytopenia | Executive Insights | US/EU5
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare, alloimmune thrombocytopenic disorder affecting fetuses / neonates, characterized in severe cases by intracranial hemorrhage. It can…
Polycythemia Vera – Current Treatment – Treatment Algorithms: Claims Data Analysis – Polycythemia Vera (US)
MARKET OUTLOOKPolycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of…
